Albireo Granted Orphan Designation by European Commission For Lead Product Candidate A4250 for Treatment of Biliary Atresia
Expands lead product candidate’s development potential in rare cholestatic liver diseases Provides 10 years market exclusivity upon approval plus 2 […]